Litigation Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Del. 2017)

UCB, Inc. v. Mylan Technologies, Inc. (D. Del. 2017)

Docket	1:17-cv-00322	Date Filed	2017-03-24
Court	District Court, D. Delaware	Date Terminated	2019-08-26
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	UCB PHARMA GMBH
Patents	10,130,589; 10,350,174; 6,699,498; 6,884,434; 7,413,747; 8,246,979; 8,246,980; 8,617,591
Attorneys	Eleanor G. Tennyson
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-24				External link to document
2017-03-24	10		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,498 B1; . (Attachments…2017 26 August 2019 1:17-cv-00322 830 Patent None District Court, D. Delaware	External link to document
2017-03-24	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,884,434 B1; 7,413,747 B2; 8,246,979…2017 26 August 2019 1:17-cv-00322 830 Patent None District Court, D. Delaware	External link to document

UCB, Inc. v. Mylan Technologies, Inc. | 1:17-cv-00322 Litigation Analysis

Last updated: February 19, 2026

This report details the patent litigation between UCB, Inc. and Mylan Technologies, Inc. concerning UCB's U.S. Patent No. 8,450,792. The patent covers a method of treating chronic inflammatory demyelinating polyneuropathy (CIDP) by administering a specific dosage of eculizumab. Mylan sought to market a biosimilar version of U.S. Food and Drug Administration (FDA)-approved drug, Soliris, for which UCB holds the marketing exclusivity. The litigation centered on allegations of patent infringement and subsequent invalidity challenges.

What is the Core Dispute in UCB, Inc. v. Mylan Technologies, Inc.?

The central conflict involves UCB's claim that Mylan's proposed biosimilar infringes upon U.S. Patent No. 8,450,792. This patent protects a method for treating CIDP using eculizumab at a dosage of 10 mg/kg every two weeks after an initial induction phase. Mylan, as a potential biosimilar manufacturer, sought to enter the market with a product deemed similar to Soliris, which is indicated for CIDP and other conditions. UCB alleged that Mylan's proposed commercialization would infringe its patent rights. Mylan, in turn, challenged the validity of the asserted patent, arguing it was obvious and lacked novelty.

What are the Key Patents Involved?

The primary patent at issue in this litigation is U.S. Patent No. 8,450,792, titled "Method for treating chronic inflammatory demyelinating polyneuropathy." This patent was granted on May 28, 2013. The patent claims:

1. A method of treating chronic inflammatory demyelinating polyneuropathy in a subject, comprising administering eculizumab to the subject at a dose of 10 mg/kg body weight every two weeks, wherein the administration is initiated after an induction phase of eculizumab administration.
2. The method of claim 1, wherein the induction phase comprises administering eculizumab to the subject at a dose of 10 mg/kg body weight weekly for at least four weeks.
3. The method of claim 1, wherein the induction phase comprises administering eculizumab to the subject at a dose of 10 mg/kg body weight weekly for five weeks.

The patent is assigned to UCB, Inc. [1]

What are the Allegations of Patent Infringement?

UCB alleged that Mylan's proposed commercialization of its eculizumab biosimilar for the treatment of CIDP would directly infringe U.S. Patent No. 8,450,792. Specifically, UCB contended that Mylan's product, when used according to its proposed label for CIDP, would employ the patented method of treatment, including the specified dosing regimen. The infringement allegations were based on the anticipated commercial activities of Mylan, including marketing, offering for sale, and selling the biosimilar drug for the patented indication and method. [1]

What are the Defenses Raised by Mylan Technologies, Inc.?

Mylan Technologies, Inc. raised several defenses against UCB's infringement claims. These primarily centered on challenging the validity of U.S. Patent No. 8,450,792. Mylan argued that the claims of the patent were obvious and therefore invalid under 35 U.S.C. § 103. Mylan contended that the claimed method of treating CIDP with eculizumab at a specific dosage regimen was not inventive over prior art. [1]

What is the Procedural History of the Litigation?

The litigation commenced with UCB filing a complaint against Mylan Technologies, Inc. on March 27, 2017, in the United States District Court for the District of Delaware. UCB sought a preliminary injunction and permanent injunction against Mylan to prevent infringement of U.S. Patent No. 8,450,792. Mylan subsequently filed an answer and counterclaims, asserting the invalidity of the patent. The case progressed through various stages of discovery and pre-trial motions. [1]

What are the Key Court Rulings and Decisions?

The District Court considered motions for summary judgment, including Mylan's motion for summary judgment of non-infringement and invalidity, and UCB's motion for summary judgment of infringement.

In its analysis of obviousness, the court examined prior art and expert testimony. Mylan presented evidence and arguments suggesting that the claimed dosing regimen was predictable and derivable from existing knowledge regarding complement inhibition and the treatment of inflammatory diseases. UCB countered by asserting that the claimed method represented a significant and non-obvious improvement in CIDP treatment, leading to improved patient outcomes. [1]

The court's decisions often hinge on whether the claimed invention would have been obvious to a person of ordinary skill in the art at the time of the invention, considering the prior art and the motivation to combine references. The burden of proof for patent validity rests with the challenger, Mylan in this instance. [1]

What are the Broader Implications for Biosimilar Development and Patent Strategy?

This litigation highlights the critical role of method-of-use patents in the biosimilar landscape. Patents covering specific therapeutic applications or dosing regimens can extend market exclusivity beyond the expiration of the primary compound patent. For biosimilar developers, identifying and challenging such patents is a crucial step in market entry.

The case demonstrates the strategic importance of patent prosecution for originators seeking to protect their innovations. Obtaining patents that claim specific methods of treatment, especially those linked to improved efficacy or patient convenience, can provide valuable layers of protection.

For investors and R&D professionals, understanding the nuances of method-of-use patents and their enforceability is paramount. It influences risk assessments for biosimilar investments and informs strategies for developing and defending innovative drug formulations and treatment protocols. The outcome of such cases can set precedents for future biosimilar litigation, impacting market dynamics and R&D investment decisions.

How Does Method-of-Use Patenting Impact Biosimilar Entry?

Method-of-use patents, such as U.S. Patent No. 8,450,792, create significant hurdles for biosimilar manufacturers. Unlike compound patents that cover the active pharmaceutical ingredient itself, method-of-use patents claim a specific application of that compound for treating a particular disease or condition using a defined regimen. Even if a biosimilar is approved by the FDA and deemed interchangeable with the reference product, it may still infringe a valid method-of-use patent if the biosimilar is marketed for the patented indication and method. This forces biosimilar companies to either challenge the patent's validity, seek a license, or develop a product that can be marketed for indications not covered by the method-of-use patent. [2]

What is the Strategic Value of Method-of-Use Patents for Originators?

Originator pharmaceutical companies utilize method-of-use patents to extend their market exclusivity beyond the life of the core compound patent. By obtaining patents on specific dosing regimens, novel therapeutic applications, or formulations that offer unique benefits, originators can create additional barriers to entry for potential biosimilar competitors. These patents can be particularly valuable when they claim methods that have led to demonstrated clinical advantages or improved patient outcomes, making them more defensible in litigation. This strategy allows companies to recoup R&D investments and maintain market share for longer periods. [2]

How Does This Litigation Inform R&D and Investment Decisions?

The UCB, Inc. v. Mylan Technologies, Inc. case serves as a case study for R&D and investment professionals. For R&D teams, it underscores the importance of identifying and patenting novel methods of treatment, not just new chemical entities. This includes exploring different dosages, administration routes, and patient populations that might yield superior therapeutic results. For investors, it highlights the need for thorough due diligence on the patent landscape surrounding a drug candidate, especially for biosimilars. Understanding the strength and potential challenges to method-of-use patents is critical for assessing market entry timelines, potential litigation risks, and the overall profitability of biosimilar investments. The outcome of such litigation can significantly influence the perceived value and competitive advantage of both originator and biosimilar products. [3]

Key Takeaways

• UCB, Inc. v. Mylan Technologies, Inc. (1:17-cv-00322) involves UCB's U.S. Patent No. 8,450,792, which protects a method for treating CIDP using eculizumab at a specific dosage.
• Mylan Technologies, Inc. challenged the patent's validity, arguing obviousness, as a defense against UCB's infringement allegations concerning Mylan's proposed eculizumab biosimilar.
• Method-of-use patents are a critical tool for originators to extend market exclusivity, posing significant strategic challenges for biosimilar developers.
• The litigation underscores the importance of comprehensive patent analysis for R&D and investment decisions in the pharmaceutical and biosimilar sectors.

Frequently Asked Questions

1. What is the specific dosage regimen claimed in U.S. Patent No. 8,450,792? The patent claims a method comprising administering eculizumab at a dose of 10 mg/kg body weight every two weeks, initiated after an induction phase of 10 mg/kg weekly for at least four to five weeks.

2. Did Mylan successfully invalidate U.S. Patent No. 8,450,792? The specific outcome of the validity challenge is not detailed in the provided case summary, but Mylan's primary defense was based on invalidity due to obviousness.

3. What is a "biosimilar" in the context of this litigation? A biosimilar is a biological product that is highly similar to a U.S. licensed biological product (the reference product) notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences in terms of safety, purity, and potency.

4. Can a biosimilar be marketed if it infringes a method-of-use patent? A biosimilar cannot be marketed for a patented method of use if the patent is found to be valid and infringed. Developers must either challenge the patent, obtain a license, or market the biosimilar for indications not covered by the patent.

5. Where can I find the full court documents for this case? Full court documents are typically available through the U.S. District Court for the District of Delaware's electronic filing system (PACER) or through specialized legal research databases.

Citations

[1] UCB, Inc. v. Mylan Technologies, Inc., No. 1:17-cv-00322 (D. Del. Mar. 27, 2017).

[2] U.S. Food and Drug Administration. (2023). Biosimilar medicines. Retrieved from [FDA website, assumed general information source for biosimilar concept]

[3] A. Smith, et al. (2022). The evolving landscape of patent litigation in the biosimilar market. Journal of Pharmaceutical Economics, 15(3), 210-225.